Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: An in vitro study

Bułdak,Rafał Jakub; Bułdak,Łukasz; Polaniak,Renata; Kukla,Michał; Birkner,Ewa; Kubina,Robert; Kabała-Dzik,Agata; Duława-Bułdak,Anna; Żwirska-Korczala,Krystyna

doi:10.3892/or.2012.2175

Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: An in vitro study

Authors:
- Rafał Jakub Bułdak
- Łukasz Bułdak
- Renata Polaniak
- Michał Kukla
- Ewa Birkner
- Robert Kubina
- Agata Kabała-Dzik
- Anna Duława-Bułdak
- Krystyna Żwirska-Korczala
View Affiliations

Affiliations: Department of Physiology, Medical University of Silesia, Zabrze, Poland, Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland, Department of General Biochemistry, Medical University of Silesia, Zabrze, Poland, Department of Pathology, Medical University of Silesia, Sosnowiec, Poland
Published online on: December 10, 2012 https://doi.org/10.3892/or.2012.2175
Pages: 771-778

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Visfatin has recently been established as a novel adipokine that is predominantly expressed in subcutaneous and visceral fat. Only few studies have investigated the effect of visfatin on prostate, breast, ovarian cancer as well as on astrocytoma cell biology. There have been no previous studies on antioxidative enzyme activities, proliferation processes or levels of DNA damage in malignant melanoma cells in response to visfatin stimulation. Here, we report that visfatin increases activity of selected antioxidative enzymes (SOD, CAT, GSH-Px) in culture supernatants of Me45 human malignant melanoma cells. Our findings suggest that visfatin triggers a redox adaptation response, leading to an upregulation of antioxidant capacity along with decreased levels of the lipid peroxidation process in Me45 melanoma cells. Moreover, visfatin led to a significantly increased proliferation rate in the study using the [3H]thymidine incorporation method. Unlike insulin, visfatin-induced melanoma cell proliferation is not mediated by an insulin receptor. Better understanding of the role of visfatin in melanoma redox states may provide sound insight into the association between obesity-related fat adipokines and the antioxidant defense system in vitro in melanoma progression.

View Figures

View References

1	Tilg H and Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 114:275–288. 2008. View Article : Google Scholar : PubMed/NCBI
2	Cappellani A, Di Vita M, Zanghi A, Cavallaro A, Piccolo G, Veroux M, Berretta M, Malaguarnera M, Canzonieri V and Lo Menzo E: Diet, obesity and breast cancer: an update. Front Biosci (Schol Ed). 4:90–108. 2012. View Article : Google Scholar
3	Thomas CC, Wingo PA, Dolan MS, Lee NC and Richardson LC: Endometrial cancer risk among younger, overweight women. Obstet Gynecol. 114:22–27. 2009. View Article : Google Scholar : PubMed/NCBI
4	Larsson SC and Wolk A: Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 97:1005–1008. 2007.PubMed/NCBI
5	Dennis LK, Lowe JB, Lynch CF and Alavanja MC: Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol. 18:214–221. 2008. View Article : Google Scholar : PubMed/NCBI
6	Oita RC, Ferdinando D, Wilson S, Bunce C and Mazzatti DJ: Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFκB-dependent manner. Pflugers Arch. 459:619–630. 2010.PubMed/NCBI
7	Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008. View Article : Google Scholar
8	Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M and Blüher M: Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 54:2911–2916. 2005. View Article : Google Scholar : PubMed/NCBI
9	Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, Komuro R and Shimomura I: Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun. 359:194–201. 2007. View Article : Google Scholar : PubMed/NCBI
10	Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J, Kiess W and Gebhardt R: Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 391:376–381. 2010. View Article : Google Scholar
11	Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W and Körner A: Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 12:1200–1211. 2011.
12	Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O and Krone W: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res. 42:268–273. 2010. View Article : Google Scholar : PubMed/NCBI
13	Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P and Halvorsen B: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 115:972–980. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M and Fasshauer M: Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci. 115:13–23. 2008. View Article : Google Scholar : PubMed/NCBI
15	Dahl TB, Holm S, Aukrust P and Halvorsen B: Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr. 32:229–243. 2012. View Article : Google Scholar : PubMed/NCBI
16	Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
17	Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y and Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307:426–430. 2005. View Article : Google Scholar : PubMed/NCBI
18	Imai S: Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 15:20–28. 2009. View Article : Google Scholar : PubMed/NCBI
19	Shackelford RE, Bui MM, Coppola D and Hakam A: Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 3:522–527. 2010.PubMed/NCBI
20	Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P and Somasundaram K: PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther. 7:663–668. 2008. View Article : Google Scholar : PubMed/NCBI
21	Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM and Randeva HS: A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 31:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
22	Park SH, Ozden O, Jiang H, Cha YI, Pennington JD, Aykin-Burns N, Spitz DR, Gius D and Kim HS: Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int J Mol Sci. 12:6226–6239. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kong W, Kuester RK, Gallegos A and Sipes IG: Induction of DNA damage in human urothelial cells by the brominated flame retardant 2,2-bis(bromomethyl)-1,3-propanediol: role of oxidative stress. Toxicology. 290:271–277. 2011. View Article : Google Scholar : PubMed/NCBI
24	Angeli JP, Garcia CC, Sena F, Freitas FP, Miyamoto S, Medeiros MH and Di Mascio P: Lipid hydroperoxide-induced and hemoglobin-enhanced oxidative damage to colon cancer cells. Free Radic Biol Med. 51:503–515. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hegde ML, Hazra TK and Mitra S: Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 18:27–47. 2008. View Article : Google Scholar : PubMed/NCBI
26	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kramer-Marek G, Serpa C, Szurko A, Widel M, Sochanik A, Snietura M, Kus P, Nunes RM, Arnaut LG and Ratuszna A: Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways. J Photochem Photobiol B. 84:1–14. 2006. View Article : Google Scholar
28	Paglia DE and Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 70:158–169. 1967.PubMed/NCBI
29	Paoletti F and Mocali A: Determination of superoxide dismutase activity by purely chemical system based on NAD(P)H oxidation. Methods Enzymol. 186:209–220. 1990. View Article : Google Scholar : PubMed/NCBI
30	Aebi H: Catalase in vitro. Methods Enzymol. 105:121–126. 1984. View Article : Google Scholar
31	Placer ZA, Cushman LL and Johnson BC: Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem. 16:359–364. 1966. View Article : Google Scholar : PubMed/NCBI
32	Olive PL and Banáth JP: Detection of DNA double-strand breaks through the cell cycle after exposure to X-rays, bleomycin, etoposide and ¹²⁵IdUrd. Int J Radiat Biol. 64:349–356. 1993. View Article : Google Scholar : PubMed/NCBI
33	Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol. 552:335–344. 2003. View Article : Google Scholar : PubMed/NCBI
34	Polaniak R, Bułdak RJ, Karoń M, Birkner K, Kukla M, Zwirska-Korczala K and Birkner E: Influence of an extremely low frequency magnetic field (ELF-EMF) on antioxidative vitamin E properties in AT478 murine squamous cell carcinoma culture in vitro. Int J Toxicol. 29:221–230. 2010. View Article : Google Scholar : PubMed/NCBI
35	Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA and Weichselbaum RR: Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res. 51:521–527. 1991.PubMed/NCBI
36	Lenehan PF, Gutiérrez PL, Wagner JL, Milak N, Fisher GR and Ross DD: Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells. Cancer Chemother Pharmacol. 35:377–386. 1995. View Article : Google Scholar
37	Gaweł S, Wardas M, Niedworok E and Wardas P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek. 57:453–455. 2004.
38	Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar : PubMed/NCBI
39	Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP and Liao EY: Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 80:201–210. 2007. View Article : Google Scholar : PubMed/NCBI
40	Haider DG, Schindler K, Schaller G, Prager G, Wolzt M and Ludvik B: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 91:1578–1581. 2006. View Article : Google Scholar
41	Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W and Imai S: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6:363–375. 2007. View Article : Google Scholar : PubMed/NCBI
42	Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH and Koo TH: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 1783:886–895. 2008. View Article : Google Scholar : PubMed/NCBI